$PFE

The US FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults 65+ and high-risk individuals 5-64. The approval is based on clinical, real-world, and manufacturing data. The vaccine targets the XFG variant and will be available in the US from autumn 2026.

The FDA approved new COVID-19 vaccines from Moderna, Pfizer-BioNTech, and Novavax-Sanofi for 2026-27, targeting current variants. Moderna received approval for two vaccines. Distribution will be limited to specific age groups and high-risk individuals, with availability expected in the fall.

Pfizer (PFE) is focusing on obesity and oncology to drive growth post-COVID-19 revenue decline. Key assets include berobenatide for obesity, targeting approvals in 2028, and several oncology candidates in late-stage development. The company aims to address upcoming patent expirations with its R&D pipeline.

PFE, GTLB, and COP stocks reached 52-week highs. PFE rose 1.65% after FDA approval of its updated COVID-19 vaccine and strong Q2 results. GTLB gained 10% on strong Q2 results and price target hikes. COP climbed 0.74% due to rising oil prices from Middle East tensions.

The FDA approved updated COVID-19 vaccines from Moderna, Pfizer, and Sanofi for the fall season. Health insurers, per AHIP, will cover these vaccines, as required by the Affordable Care Act. Uninsured individuals may access free vaccines through state or federal programs. The vaccines target specific high-risk groups, with recommendations from the AAFP and CDC.

Texas AG Ken Paxton is appealing a dismissal of his lawsuit against Pfizer, alleging the company misrepresented COVID-19 vaccine efficacy. The Fifth Circuit heard arguments, with judges questioning jurisdiction and Pfizer's immunity claims. Pfizer argues it acted under federal direction and is protected by the PREP Act.

Pfizer (PFE) reported Q2 revenue of $15B (+1% YoY) and EPS of $0.77, both beating estimates. Non-COVID revenue grew 5% YoY, while launched/acquired products sales jumped 18%. The company faces patent cliffs, including Eliquis, and clinical setbacks. Pfizer's pipeline includes 95 active programs, with 56 for new molecular entities. Analysts debate its growth prospects and dividend safety.

The FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax targeting the JN.1-lineage XFG variant. Approvals cover high-risk populations, including adults 65+ and those with underlying conditions. Pfizer and Moderna's mRNA vaccines and Novavax's protein-based vaccine are now authorized for distribution.

Jim Cramer declined to recommend Pfizer (PFE) despite its 7% dividend, citing lack of growth prospects. Pfizer's Q2 2026 revenue was $15.0B, beating estimates, but net income fell. Cramer noted challenges from patent cliffs and COVID vaccine declines. Analysts now rate PFE a 'Buy' with an average target of $28.61.

Pfizer's shares reached a new 52-week high, up 1.89% to $29.09, driven by a drug pricing deal with the Trump administration, strong Q2 earnings, and a legal settlement. The company beat EPS estimates and raised its 2026 guidance. Concerns remain about long-term growth and patent expirations.